Cargando…

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC

BACKGROUND: Non‐small‐cell lung cancer (NSCLC) is the leading cause of death from cancer in China. Gefitinib is effective for patients with positive epidermal growth factor receptor gene mutation; however, acquired drug resistance counteracts the duration response. Hyperthermia is widely clinically...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Yijia, Sun, Yu, Liu, Yongmei, Luo, Yiqiao, Zhu, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930961/
https://www.ncbi.nlm.nih.gov/pubmed/27385984
http://dx.doi.org/10.1111/1759-7714.12346
_version_ 1782440809539305472
author Qin, Yijia
Sun, Yu
Liu, Yongmei
Luo, Yiqiao
Zhu, Jiang
author_facet Qin, Yijia
Sun, Yu
Liu, Yongmei
Luo, Yiqiao
Zhu, Jiang
author_sort Qin, Yijia
collection PubMed
description BACKGROUND: Non‐small‐cell lung cancer (NSCLC) is the leading cause of death from cancer in China. Gefitinib is effective for patients with positive epidermal growth factor receptor gene mutation; however, acquired drug resistance counteracts the duration response. Hyperthermia is widely clinically applied in the treatment of solid tumors. This pilot study was designed to evaluate the feasibility of the combination of gefitinib and hyperthermia. METHODS: Patients newly diagnosed with advanced NSCLC were screened. Eleven patients who responded to first‐line gefitinib treatment were enrolled in the study. Along with 250 mg gefitinib daily, local radiofrequency hyperthermia was administered twice a week until tumor progression was observed. The serum, heat shock protein (HSP)70, was also frequently detected during the course. RESULTS: The most common toxicity included skin rash (81.8%) and abnormal liver function (45.5%) when treated with gefitinib, and fatty scleroma (36.4%) was observed when combined with hyperthermia. Grade 3 side effects (skin rash) occurred in only one patient. Median progression‐free survival was 22 months (95% confidence interval [CI]: 12.95–31.05 months) and median overall survival was 26 months (95% CI: 22.81–29.19 months). Serum HSP70 concentration increased and maintained a significantly high level compared with the baseline before hyperthermia administration. CONCLUSIONS: The novel therapy of gefitinib combined with radiofrequency hyperthermia is safe and effective for advanced NSCLC patients. Whether an improvement in therapeutic efficacy is associated with the elevation of serum HSP70 concentration requires further study.
format Online
Article
Text
id pubmed-4930961
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-49309612016-07-06 Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC Qin, Yijia Sun, Yu Liu, Yongmei Luo, Yiqiao Zhu, Jiang Thorac Cancer Original Articles BACKGROUND: Non‐small‐cell lung cancer (NSCLC) is the leading cause of death from cancer in China. Gefitinib is effective for patients with positive epidermal growth factor receptor gene mutation; however, acquired drug resistance counteracts the duration response. Hyperthermia is widely clinically applied in the treatment of solid tumors. This pilot study was designed to evaluate the feasibility of the combination of gefitinib and hyperthermia. METHODS: Patients newly diagnosed with advanced NSCLC were screened. Eleven patients who responded to first‐line gefitinib treatment were enrolled in the study. Along with 250 mg gefitinib daily, local radiofrequency hyperthermia was administered twice a week until tumor progression was observed. The serum, heat shock protein (HSP)70, was also frequently detected during the course. RESULTS: The most common toxicity included skin rash (81.8%) and abnormal liver function (45.5%) when treated with gefitinib, and fatty scleroma (36.4%) was observed when combined with hyperthermia. Grade 3 side effects (skin rash) occurred in only one patient. Median progression‐free survival was 22 months (95% confidence interval [CI]: 12.95–31.05 months) and median overall survival was 26 months (95% CI: 22.81–29.19 months). Serum HSP70 concentration increased and maintained a significantly high level compared with the baseline before hyperthermia administration. CONCLUSIONS: The novel therapy of gefitinib combined with radiofrequency hyperthermia is safe and effective for advanced NSCLC patients. Whether an improvement in therapeutic efficacy is associated with the elevation of serum HSP70 concentration requires further study. John Wiley & Sons Australia, Ltd 2016-03-24 2016-07 /pmc/articles/PMC4930961/ /pubmed/27385984 http://dx.doi.org/10.1111/1759-7714.12346 Text en © 2016 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Qin, Yijia
Sun, Yu
Liu, Yongmei
Luo, Yiqiao
Zhu, Jiang
Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
title Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
title_full Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
title_fullStr Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
title_full_unstemmed Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
title_short Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
title_sort pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced nsclc
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930961/
https://www.ncbi.nlm.nih.gov/pubmed/27385984
http://dx.doi.org/10.1111/1759-7714.12346
work_keys_str_mv AT qinyijia pilotstudyofradiofrequencyhyperthermiaincombinationwithgefitinibingefitinibeffectivepatientswithadvancednsclc
AT sunyu pilotstudyofradiofrequencyhyperthermiaincombinationwithgefitinibingefitinibeffectivepatientswithadvancednsclc
AT liuyongmei pilotstudyofradiofrequencyhyperthermiaincombinationwithgefitinibingefitinibeffectivepatientswithadvancednsclc
AT luoyiqiao pilotstudyofradiofrequencyhyperthermiaincombinationwithgefitinibingefitinibeffectivepatientswithadvancednsclc
AT zhujiang pilotstudyofradiofrequencyhyperthermiaincombinationwithgefitinibingefitinibeffectivepatientswithadvancednsclc